Thymosin Alpha-1 (Zadaxin) Side Effects and Safety
Side effects series
Thymosin alpha-1 side effects are, unusually for a “research peptide,” backed by a real drug label and randomized-trial data. Marketed abroad as Zadaxin (thymalfasin), it has been given to thousands of patients — which makes it a useful, honest contrast to compounds with no human safety record at all. Here is what the label and the trials actually report, and where the real risk lies.
Thymosin alpha-1 side effects: what the label reports
Thymosin alpha-1 is a 28-amino-acid thymic peptide sold under the brand Zadaxin and approved in more than 30 countries for chronic hepatitis B and related uses. Its manufacturer’s label describes it as well tolerated: across clinical experience involving over 2,000 individuals spanning all age groups, it reports under 1% drug-related adverse events for all indications.
The specific adverse experiences the label lists are infrequent and mild:
- Local discomfort at the injection site — the most commonly noted effect.
- Rare erythema (redness) and rash.
- Rare transient muscle atrophy, and polyarthralgia (joint pain) combined with hand edema.
- In hepatitis B specifically, a transient ALT flare can occur during treatment — a biochemical change, not a classic side effect, generally managed by continuing therapy unless liver-failure signs appear.
Importantly, the label gives no per-symptom percentage — only “infrequent and mild.” Any vendor page that lists precise side-effect rates for thymosin alpha-1 is inventing them.
The rare research peptide with a real dossier
What sets this compound apart is that its safety claims rest on an actual regulatory record rather than anecdote.
It is approved and marketed in dozens of countries, carries a manufacturer label with an adverse-event summary, and has been tested in randomized controlled trials. That is a very different evidence base from most peptides in the research market — but, as below, it comes with sharp limits.
What the trials show about safety
The strongest single safety dataset comes from the ETASS trial (Wu et al., 2013), a multicenter randomized controlled study of 361 patients with severe sepsis. On safety, the trial reported no drug-related serious adverse events and no treatment discontinuations due to intolerance, with no significant between-group differences in laboratory or organ-system measures. The trial also reported a mortality signal in favor of thymosin alpha-1, but that efficacy finding has been debated in later analyses — treat it as a signal, not settled proof, while the tolerability finding is robust.
Hepatitis B trials (for example, Chien and colleagues, 1998) similarly supported tolerability alongside efficacy questions. COVID-19 studies exist too, but they are contested: one retrospective report suggested a mortality benefit, while other work found no effect on restoring T-cell counts. The safety takeaway is consistent (few drug-related adverse events); the efficacy story is mixed.
What is NOT established
The same label that reports good tolerability is candid about its blind spots:
- Long-term and cancer risk: long-term carcinogenicity studies have not been done (mutagenicity studies were negative).
- Under age 18: safety and effectiveness have not been established.
- Pregnancy: Category C — animal signals were unremarkable, but human data are absent.
- Immune context: because it augments immune function, it is considered contraindicated in deliberately immunosuppressed patients (such as transplant recipients) unless the benefit clearly outweighs the risk. Over-activation of the immune system is a theoretical concern, not a documented trial finding.
The real-world risk: product quality, not just the molecule
For material bought outside a pharmacy, the concrete danger is usually not the peptide’s intrinsic profile — it is what is in the vial. Endotoxin contamination, non-sterility, misidentification, and inaccurate dosing are the failure modes for any injectable research compound, and they are exactly the variables that trials control and grey-market supply does not. If you are handling any lyophilized peptide, our guides on reconstitution and sterile technique cover the basics that reduce (but never eliminate) that risk.
Regulatory status
Thymosin alpha-1 is not FDA-approved in the United States for any indication; it holds US orphan-drug designations only, which are development incentives rather than marketing approval. As of 2026, its status as a compounding substance has been contested and is under FDA review — check the current FDA bulk-substances materials for the latest. Athletes should note that thymosin beta-4 is prohibited under the WADA code; anyone competing should verify the current WADA Prohibited List directly rather than assume. You can find the verified chemistry and references on our thymosin alpha-1 library page.
Frequently asked questions
Is thymosin alpha-1 FDA-approved?
No. It is approved in more than 30 other countries (as Zadaxin) but is not FDA-approved in the United States, where it holds only orphan-drug designations.
What are the most common thymosin alpha-1 side effects?
Per the manufacturer label, the most commonly noted effect is local discomfort at the injection site, with rare reports of redness, rash, transient muscle atrophy, and joint pain with hand swelling. Overall drug-related adverse events were under 1% across indications.
Is it safe for long-term use?
That is not established. The label explicitly states long-term carcinogenicity studies have not been done, and safety in people under 18 and in pregnancy has not been established.
Why do the trials look reassuring if it is risky?
The trials used pharmaceutical-grade product under medical supervision. Grey-market vials reintroduce the sterility, endotoxin, identity, and dosing risks that trials specifically control for — so trial tolerability does not transfer to unregulated material.
- SciClone. ZADAXIN (thymalfasin) prescribing information — description, indications, side effects (RxList). rxlist.com
- Wu J, et al. Efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized controlled trial. Critical Care. 2013;17:R8. ccforum.biomedcentral.com
- Liu Y, et al. Thymosin alpha 1 reduces the mortality of severe COVID-19 by restoration of lymphocytopenia. Clin Infect Dis. 2020 (PMC7314217). pmc.ncbi.nlm.nih.gov
- Thymosin alpha-1 has no beneficial effect on restoring CD4+/CD8+ counts in COVID-19 (counter-evidence). Front Immunol. 2021 (PMC8209490). ncbi.nlm.nih.gov
- Chien RN, Liaw YF, et al. Efficacy of thymosin alpha-1 in chronic hepatitis B: a randomized controlled trial. Hepatology. 1998;27:1383-1387 (PMID 9581692). pubmed.ncbi.nlm.nih.gov/9581692
- ClinicalTrials.gov. Efficacy of Thymosin alpha 1 for Severe Sepsis (NCT00711620). clinicaltrials.gov
Informational only — not medical advice. For research and educational use by adults 21+. Thymosin alpha-1 is not FDA-approved in the United States. Consult a qualified professional for medical decisions.
In Plain English
BPC-157 is a lab-made copy of a small piece of a protein found naturally in the stomach. In animal studies it appears to help injured tissue — like muscle, tendon, and the gut lining — heal faster. Researchers are interested in it as a possible all-purpose recovery aid, but almost all of the evidence so far comes from animals rather than people.
BPC-157 (Body Protection Compound-157) is a synthetic chain of 15 amino acids based on a sequence found in human gastric juice. First described by a research group in Zagreb in the early 1990s, it has become one of the most-studied “healing” peptides in preclinical science. This profile summarizes what BPC-157 is, how researchers describe its activity, and what the published literature actually shows — for informational purposes only.
What is BPC-157?
BPC-157 is a stable gastric pentadecapeptide — “pentadecapeptide” simply means a peptide of fifteen amino acids. It is a partial sequence derived from a larger body-protection compound isolated from gastric juice, and it is notably stable in human gastric acid, which is part of why it attracted research interest. You may also see it referred to as Body Protection Compound 157, PL 14736, or bepecin. It is a research compound and is not approved by the FDA or other regulators for human use.
How BPC-157 is studied to work
Across animal studies, researchers have proposed several overlapping mechanisms rather than a single mode of action. The most consistently reported is an effect on angiogenesis — the formation of new blood vessels — which supports tissue repair by improving blood supply to an injured area.
- VEGFR2 activation: BPC-157 is reported to up-regulate and activate the VEGFR2 receptor, a central switch in blood-vessel growth.
- Nitric-oxide pathway: downstream signaling through the Src–Caveolin-1–eNOS pathway is described, increasing nitric-oxide availability and influencing vascular tone.
- Growth-factor and Egr-1 signaling: studies also point to interactions with growth-factor pathways and early growth response factor-1, which help coordinate cell migration and repair.
A 2025 narrative review in Current Reviews in Musculoskeletal Medicine organized three decades of work around four mechanistic pillars: VEGFR2-mediated angiogenesis, eNOS coupling, ERK1/2 signaling, and anti-inflammatory modulation. Importantly, almost all of this evidence comes from cell and rodent models.
Reported effects and benefits in the research literature
In published animal research, the effects most often associated with BPC-157 cluster around connective-tissue repair and protection of the gut. These are the outcomes that have driven interest in the peptide:
- Tendon and ligament models: faster healing, tendon-cell outgrowth, and improved cell survival and migration after injury.
- Muscle injury: recovery signaling reported after crush and strain injuries in rodents.
- Gastrointestinal tract: protective effects on the stomach lining and gut in ulcer and inflammatory-bowel models — consistent with its gastric-juice origin.
- Blood vessels and wound healing: pro-angiogenic activity linked to the VEGFR2 / nitric-oxide pathway described above.
What this does not mean: these are preclinical findings. They should not be read as evidence that BPC-157 is safe or effective in people. The enthusiasm often seen online runs well ahead of the controlled human data, which remains very limited.
What the human evidence shows
Well-controlled human trials of BPC-157 are lacking. The bulk of the literature is animal and laboratory work, much of it from a single research group, with a growing but still small set of independent replications. Because of this evidence gap, regulators have taken a cautious stance.
In September 2023, the U.S. FDA placed BPC-157 in its Category 2 list of bulk drug substances for compounding — substances flagged as potentially presenting significant safety risks. The agency cited concerns including possible immunogenicity for certain routes of administration and difficulty characterizing peptide-related impurities, alongside limited safety data. In practice this restricts traditional compounding pharmacies from preparing it.
Handling, storage and reconstitution (research context)
Like most research peptides, BPC-157 is typically supplied as a lyophilized (freeze-dried) powder that is reconstituted with bacteriostatic water before use in the lab.
- Lyophilized powder: store cool and dark; long-term storage is usually at −20°C.
- After reconstitution: refrigerate at 2–8°C and use within a few weeks.
- Measurement: work in concentration (mg/mL) and volume rather than “units.” Our reconstitution calculator turns vial mg + water volume into concentration and draw volume, and the explainer IU vs mL: why “units” are not a dose clears up the most common measurement mistake.
Cautions and considerations
- BPC-157 is a research compound and is not FDA-approved; it is not a medicine.
- Human safety and efficacy are not established — most evidence is preclinical.
- Purity and identity vary between sources; a Certificate of Analysis (COA) showing purity and identity is essential for any research-grade material.
- This page is informational only and is not medical advice.
Frequently asked questions
Is BPC-157 FDA-approved?
No. BPC-157 is not approved for human use, and in 2023 the FDA placed it on its Category 2 bulk-substances list, citing safety concerns and limited data.
What is BPC-157’s molecular weight and formula?
BPC-157 has the molecular formula C62H98N16O22 and a molecular weight of about 1419.5 g/mol (CAS 137525-51-0).
What is its half-life?
Reported plasma half-life is short — on the order of minutes — though detailed human pharmacokinetic data are limited.
How is BPC-157 stored?
As a lyophilized powder it is kept cool and dark (long-term −20°C); once reconstituted it is refrigerated at 2–8°C and used within a few weeks.
Related compounds and further reading
- Ipamorelin — a selective growth-hormone secretagogue studied in a different research area.
- Browse the full peptide library for more compound profiles.
- Storage, stability and handling guides for research peptides.
- IU vs mL: why “units” are not a dose — the measurement basics behind every calculation.
- How to reconstitute peptides — step-by-step reconstitution method and concentration math.
- Sterile technique — aseptic handling and contamination prevention for research vials.